Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Total Liabilities (2016 - 2025)

Catalyst Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at $149.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 20.95% year-over-year to $149.7 million; the TTM value through Dec 2025 reached $149.7 million, up 20.95%, while the annual FY2025 figure was $149.7 million, 20.95% up from the prior year.
  • Total Liabilities reached $149.7 million in Q4 2025 per CPRX's latest filing, up from $131.4 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $149.7 million in Q4 2025 to a low of $18.6 million in Q1 2021.
  • Average Total Liabilities over 5 years is $75.2 million, with a median of $74.4 million recorded in 2022.
  • Peak YoY movement for Total Liabilities: dropped 0.12% in 2021, then surged 175.0% in 2023.
  • A 5-year view of Total Liabilities shows it stood at $31.0 million in 2021, then soared by 142.95% to $75.2 million in 2022, then increased by 9.34% to $82.2 million in 2023, then soared by 50.52% to $123.8 million in 2024, then grew by 20.95% to $149.7 million in 2025.
  • Per Business Quant, the three most recent readings for CPRX's Total Liabilities are $149.7 million (Q4 2025), $131.4 million (Q3 2025), and $115.9 million (Q2 2025).